Development of Chimeric Antigen Receptor-Expressing iPSC-Derived Macrophages with Improved Anti-Tumor Activity

诱导多能干细胞 生物 吞噬作用 CD80 造血 趋化因子 CD40 免疫学 免疫系统 细胞生物学 癌症研究 干细胞 体外 细胞毒性T细胞 生物化学 基因 胚胎干细胞
作者
Somayeh Pouyanfard,Manuel Fierro,Dan S. Kaufman
出处
期刊:Blood [American Society of Hematology]
卷期号:138 (Supplement 1): 1693-1693 被引量:3
标识
DOI:10.1182/blood-2021-148687
摘要

Abstract Previous studies by our group demonstrate the ability to routinely derive hematopoietic and immune cells from human pluripotent stem cells. Here, we demonstrate the efficient derivation of macrophages from human induced pluripotent stem cells (iPSCs). These macrophages have phenotypic and genotypic characteristics similar to monocytes/macrophages isolated from human peripheral blood. We also demonstrate the ability to polarize these iPSC-derived macrophages (iPSC-Macs) to M1 and M2 populations. Specifically, M1 iPSC-Macs have pro-inflammatory characteristics including expression of CD40 and CD80 on the cell surface, produce increased amounts of TNF-a and IL-6 detected in the supernatant, as well have increased expression of inflammatory cytokines/chemokines (TNF-a, IL-6, IL-1b, IL-12, CCL2, CCL3 and TRAIL) and increased expression of matrix metalloproteases (MMPs). Function of these iPSC-Macs was initially assessed by phagocytosis of fluorescently-labeled beads. These studies demonstrated both the iPSC-M1 and M2 macrophages efficiently phagocytized these beads, and at similar amounts as their peripheral blood counterparts. Next, we tested the ability of the iPSC-Macs to phagocytize human tumor cells. Using A1847 ovarian tumor cells, we found while the iPSC-Macs alone had limited ability to phagocytize the tumor cells (9%), addition of either an anti-CD47 mAb (41%) or anti-EGFR (41%) lead to markedly increased phagocytosis, with the combination of the 2 antibodies being even better (55% phagocytosis). We then tested iPSC-Macs in vivo against luciferase (luc)-expressing A1847 ovarian cancer cells as a xenograft model in NSG-SGM3 mice that express human IL3, GM-CSF and SCF. Using bioluminescent imaging, we found that the combination of iPSC-Macs with both anti-CD47 and anti-EGFR demonstrated significantly improved anti-tumor activity, with median survival of 75 days, compared to 50-60 days for mice treated with only iPSC-Macs, only mAbs or with iPSC-Macs combined either single mAb. Next, we aimed to use the iPSC platform to produce iPSC-Macs engineered to express chimeric antigen receptors (CARs) to further improve their anti-tumor activity. Here, we developed and tested novel macrophage specific CARs that were stably expressed in undifferentiated iPSCs using transposon-mediated gene transfer, similar to our previous studies to derive iPSC-derived CAR-expressing NK cells that have now been translated into clinical trials. We used an anti-mesothelin (meso) scFv combined with 8 different CAR constructs with distinct intracellular signaling components. We found that the iPSC-Macs could express good levels of the CARs (iPSC-CarMacs). Function was again tested in vitro by phagocytosis of the Meso+ A1847 ovarian cancer cells. The iPSC-CarMacs with a Bai1 stimulatory domain consistently demonstrated the best activity in this assay system. We next tested the anti-meso-iPSC-CarMacs in vivo using the A1847 cells. Again, we demonstrate the iPSC-CarMacs combined with anti-CD47 mAb mediate significantly improved anti-tumor activity using this in vivo model compared to the non-CAR-iPSC-Macs + anti-CD47, p <0.005 (Figure). Survival studies are still ongoing. Together, these studies demonstrate that iPSCs can be used to routinely and efficiently derive macrophages with potent anti-tumor activity. Additionally, CARs that are optimized for macrophage-mediated activity can be expressed to generate iPSC-CarMacs that effectively kill tumor cells in vitro and in vivo. These iPSC-CarMacs provide another approach to provide a standardized, targeted, off-the-shelf cell therapy product that can be used to treat both hematological malignancies as well as diverse solid tumors. Figure 1 Figure 1. Disclosures Kaufman: Shoreline Biosciences: Consultancy, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Research Funding; Qihan Biotech: Consultancy, Current holder of stock options in a privately-held company; VisiCELL Medical: Consultancy, Current holder of stock options in a privately-held company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
烟花应助Eason采纳,获得10
刚刚
勤劳不二发布了新的文献求助10
1秒前
漂亮灵阳完成签到,获得积分10
1秒前
3秒前
平凡完成签到,获得积分10
3秒前
小二郎应助科研通管家采纳,获得10
4秒前
汉堡包应助科研通管家采纳,获得10
4秒前
香蕉觅云应助科研通管家采纳,获得10
4秒前
小蘑菇应助科研通管家采纳,获得10
4秒前
LIU发布了新的文献求助10
4秒前
轻松水瑶应助科研通管家采纳,获得10
4秒前
香蕉觅云应助科研通管家采纳,获得10
4秒前
顾矜应助科研通管家采纳,获得10
4秒前
4秒前
LIU发布了新的文献求助10
4秒前
5秒前
5秒前
5秒前
5秒前
Jasper应助Ywffffff采纳,获得10
6秒前
he完成签到 ,获得积分10
7秒前
mgr完成签到,获得积分10
7秒前
良辰应助PTDRA采纳,获得10
8秒前
良辰应助PTDRA采纳,获得10
8秒前
良辰应助PTDRA采纳,获得10
8秒前
良辰应助PTDRA采纳,获得10
8秒前
领导范儿应助123采纳,获得10
8秒前
肥女姐姐发布了新的文献求助10
8秒前
慕青应助here采纳,获得30
9秒前
反杀闰土的猹完成签到,获得积分10
10秒前
石子完成签到,获得积分10
10秒前
TristanW发布了新的文献求助10
11秒前
小二郎应助za采纳,获得10
11秒前
11秒前
ding应助杨天水采纳,获得10
11秒前
迷人的又亦完成签到,获得积分10
11秒前
罗_应助hhh采纳,获得10
11秒前
传奇3应助卓涵柏采纳,获得10
12秒前
Jane完成签到,获得积分10
12秒前
CipherSage应助三木足球采纳,获得10
12秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Kelsen’s Legacy: Legal Normativity, International Law and Democracy 1000
Handbook on Inequality and Social Capital 800
Conference Record, IAS Annual Meeting 1977 610
Interest Rate Modeling. Volume 3: Products and Risk Management 600
Interest Rate Modeling. Volume 2: Term Structure Models 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3546676
求助须知:如何正确求助?哪些是违规求助? 3123726
关于积分的说明 9356475
捐赠科研通 2822353
什么是DOI,文献DOI怎么找? 1551369
邀请新用户注册赠送积分活动 723332
科研通“疑难数据库(出版商)”最低求助积分说明 713721